Inhibrx (Inhibrx) Net Margin %

: -5,728.52% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Inhibrx's Net Income for the three months ended in Dec. 2023 was $-93.60 Mil. Inhibrx's Revenue for the three months ended in Dec. 2023 was $1.63 Mil. Therefore, Inhibrx's net margin for the quarter that ended in Dec. 2023 was -5,728.52%.

The historical rank and industry rank for Inhibrx's Net Margin % or its related term are showing as below:

INBX' s Net Margin % Range Over the Past 10 Years
Min: -13408.94 Med: -594.35 Max: -244.55
Current: -13408.94

INBX's Net Margin % is ranked worse than
92.6% of 1027 companies
in the Biotechnology industry
Industry Median: -163.32 vs INBX: -13408.94

Inhibrx Net Margin % Historical Data

The historical data trend for Inhibrx's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-565.27

-594.35

-1,147.62

-6,667.86

-13,408.94

Inhibrx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-14,932.48	-287,741.18	-156,840.00	-43,520.17	-5,728.52

Competitive Comparison

For the Biotechnology subindustry, Inhibrx's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibrx Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Inhibrx's Net Margin % distribution charts can be found below:

* The bar in red indicates where Inhibrx's Net Margin % falls into.

Inhibrx Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Inhibrx's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-241.361	/	1.8
	=	-13,408.94 %

Inhibrx's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-93.604	/	1.634
	=	-5,728.52 %

Inhibrx (NAS:INBX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Inhibrx Net Margin % Related Terms

Thank you for viewing the detailed overview of Inhibrx's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx (Inhibrx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Inc (NAS:INBX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.

Executives

Ole Andreas Halvorsen	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Mark Lappe	director, 10 percent owner, officer: Chief Executive Officer	11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Brendan P. Eckelman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jon Faiz Kayyem	director, 10 percent owner	5964 LA PLACE COURT, CARLSBAD CA 92008
Dragsa 50 Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Klaus W. Wagner	officer: Chief Medical Officer	C/O INHIBRX, INC., 11025 N. TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Kimberly Manhard	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121